Key terms
About LUMO
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest LUMO news
Mar 20
11:45am ET
Lumos Pharma’s LUM-201 Receives ‘Buy’ Rating on Strong Market Position and Promising Trial Outcomes
Mar 20
8:02am ET
Lumos Pharma receives notice of allowance from USPTO for LUM-201 patent
Mar 08
7:50am ET
Analysts Are Bullish on Top Healthcare Stocks: Poseida Therapeutics (PSTX), Lumos Pharma (LUMO)
Mar 08
6:30am ET
Analysts Are Bullish on Top Healthcare Stocks: Lumos Pharma (LUMO), Arcturus Therapeutics (ARCT)
Mar 07
4:16pm ET
Lumos Pharma reports Q4 EPS ($1.17), consensus ($1.15)
Jan 04
5:12pm ET
Lumos Pharma promotes Pisit Pitukcheewanont, MD to CMO, effective January 1
No recent news articles are available for LUMO
No recent press releases are available for LUMO
LUMO Financials
Key terms
Ad Feedback
LUMO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LUMO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
